Edition:
United States

Repros Therapeutics Inc (RPRX.PH)

RPRX.PH on Philadelphia Stock Exchange

0.32USD
3 Aug 2017
Change (% chg)

-- (--)
Prev Close
$0.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,181
52-wk High
$2.45
52-wk Low
$0.32

Latest Key Developments (Source: Significant Developments)

Repros requests meeting with FDA to discuss phase 3 requirements for proellex in the treatment of symptomatic uterine fibroids
Monday, 12 Dec 2016 04:01pm EST 

Repros Therapeutics Inc : Says company anticipates a meeting will be scheduled during first half of 2017 . Repros Therapeutics Inc - objective of meeting with fda is primarily to agree on phase 3 clinical program .Repros requests meeting with FDA to discuss phase 3 requirements for proellex in the treatment of symptomatic uterine fibroids.  Full Article

Repros says groups showed improvement in Enclomiphene study
Monday, 15 Aug 2016 04:01pm EDT 

Repros Therapeutics Inc : Repros provides six month interim results for Enclomiphene study in obese secondary Hypogonadal men .All groups showed statistically significant improvement in all metabolic parameters tested..  Full Article

Repros Therapeutics - entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million
Tuesday, 9 Aug 2016 04:25pm EDT 

Repros Therapeutics Inc :Entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million.  Full Article

Repros Therapeutics Inc. reported Q2 EPS ($0.18)
Tuesday, 9 Aug 2016 09:15am EDT 

Repros Therapeutics Inc : Repros Therapeutics Inc. reports second quarter 2016 financial results .Q2 loss per share $0.18.  Full Article

Repros Therapeutics reports Q1 loss per share of $0.20
Tuesday, 10 May 2016 09:15am EDT 

Repros Therapeutics Inc : Repros therapeutics inc.® reports first quarter 2016 financial results .Q1 loss per share $0.20.  Full Article

BRIEF-Rosalind Advisors reports 5.7 pct stake in Repros Therapeutics

* Rosalind Advisors Inc reports 5.7 percent passive stake in Repros Therapeutics Inc as of July 20 - SEC filing Source text: (http://bit.ly/2gXOAhU) Further company coverage: